Understand the source comparison
Best Cartalax Dosage for Bone Health: Comparison
0.2–0.3mg 20 days Single cycle Biochemical marker elevation (alkaline phosphatase +8–12%) Anti-aging, soft tissue support Insufficient potency for measurable bone density change. Appropriate for cellular aging research but not skeletal outcomes 0.5mg 20 days ×
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 0.2–0.3mg
- 20 days
- Single cycle
- Biochemical marker elevation (alkaline phosphatase +8–12%)
- Anti-aging, soft tissue support
- Insufficient potency for measurable bone density change. Appropriate for cellular aging research but not skeletal outcomes
- 0.5mg
- 20 days × 3 cycles
- 20 on / 10 off
- Osteoblast proliferation +14–18%, collagen synthesis increase
- Bone maintenance in healthy adults
- Minimum effective dose for bone health when combined with resistance training. Cost-effective for long-term maintenance
- 1.0mg
- Osteoblast proliferation +18–24%, radiographic density improvement (DXA scan)
- Active bone loss intervention, post-injury recovery
- Optimal dose for documented bone health deficits. Produces measurable DXA improvements when paired with mechanical loading
- 1.5mg+
- No additional benefit vs 1.0mg
- Not recommended
- Receptor saturation occurs around 1.2mg. Higher doses waste peptide without proportional efficacy gains
- The table demonstrates dose-response relationship: 0.5mg is the minimum effective dose for bone-specific outcomes, 1.0mg produces maximal benefit, and doses above 1.5mg offer no additional structural advantage. Cycle structure (three 20-day cycles with 10-day rest periods) remains constant across all effective protocols.